Integration of genomic variants and bioinformatic-based approach to drive drug repurposing for multiple sclerosis.

ABSTRACT: Multiple sclerosis (MS) is a chronic autoimmune disease in the central nervous system (CNS) marked by inflammation, demyelination, and axonal loss. Currently available MS medication is limited, thereby calling for a strategy to accelerate new drug discovery. One of the strategies to discover new drugs is to utilize old drugs for new indications, an approach known as drug repurposing. Herein, we first identified 421 MS-associated SNPs from the Genome-Wide Association Study (GWAS) catalog (p-value < 5 × 10^-8), and a total of 427 risk genes associated with MS using HaploReg version 4.1 under the criterion r² > 0.8. MS risk genes were then prioritized using bioinformatics analysis to identify biological MS risk genes. The prioritization was performed

SUBMITTER: Afief AR 

PROVIDER: S-EPMC9464879 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature